Related Experiment Video
Updated: May 7, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Comparative analysis for optimal LSD1 inhibitors evaluation techniques: pros and cons
Qiange Yin1,2, Congcong Ma1, Xiaoying Zhao1
1State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Small Molecule Drug Discovery and Application, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Abstract:
Aberrant expression of lysine-specific demethylase 1 (LSD1) has been consistently implicated in a broad spectrum of malignancies, underscoring its relevance as a therapeutic target. Despite growing interest, the development of LSD1 inhibitors continues to face significant challenges, in part due to the enzyme's dual role in catalysis and as a scaffolding protein within chromatin-remodeling complexes. Recent insights into the non-enzymatic functions of LSD1 have shifted the focus toward disrupting its protein-protein interactions, particularly with chromatin-modifying enzymes, as a complementary or alternative therapeutic strategy. In light of the limited systematic evaluation of available technologies, this work provides a critical overview and comparative analysis of current screening platforms and binding affinity assays, with particular attention to approaches capable of identifying LSD1 scaffold inhibitors. These efforts aim to accelerate the discovery of next-generation LSD1-targeted therapies with improved translational potential in oncology.
Insights
Lysine-specific demethylase 1 (LSD1) is a cancer target, but its dual role poses challenges. This study reviews methods to find new therapies targeting LSD1's scaffolding functions, not just its enzymatic activity.
Area of Science:
- Oncology
- Biochemistry
- Drug Discovery
Background:
- Aberrant expression of lysine-specific demethylase 1 (LSD1) is linked to various cancers, making it a key therapeutic target.
- LSD1's dual role as a catalytic enzyme and a scaffolding protein in chromatin remodeling complicates inhibitor development.
- Emerging research highlights LSD1's non-enzymatic functions, suggesting disruption of protein-protein interactions as a novel therapeutic strategy.
Purpose of the Study:
- To critically review and compare current screening platforms and binding affinity assays for identifying LSD1 inhibitors.
- To focus on technologies capable of discovering inhibitors targeting LSD1's scaffolding functions.
- To accelerate the development of next-generation LSD1-targeted cancer therapies.
Main Methods:
- Systematic evaluation of existing technologies for LSD1 inhibitor screening.
- Comparative analysis of binding affinity assays.
- Focus on assays suitable for identifying LSD1 scaffold inhibitors.
Main Results:
- Provides a comprehensive overview of current screening and assay technologies relevant to LSD1.
- Highlights the limitations and strengths of different approaches for targeting LSD1's scaffolding role.
- Identifies key technologies for advancing the discovery of novel LSD1 inhibitors.
Conclusions:
- Disrupting LSD1's protein-protein interactions offers a promising therapeutic avenue in oncology.
- Systematic evaluation of screening platforms is crucial for identifying effective LSD1 scaffold inhibitors.
- This work aims to guide the development of more translatable LSD1-targeted therapies.
Related Concept Videos
01:26Drug Discovery: Overview
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems